Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules

被引:72
作者
Zhuang, HM
Hickeson, M
Chacko, TK
Duarte, PS
Nakhoda, KZ
Feng, Q
Alavi, A
机构
[1] Hosp Univ Penn, Div Nucl Med, Dept Radiol, Philadelphia, PA 19104 USA
[2] Fleury Lab, Nucl Med Sect, Sao Paulo, SP, Brazil
关键词
colon cancer; fluorodeoxyglucose; positron emission tomography; pulmonary nodule;
D O I
10.1097/00003072-200209000-00004
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: Fluorodeoxyglucose (FDG) positron emission tomographic (PET) imaging has been used extensively to diagnose cancer with high rates of sensitivity and specificity. One of its applications is to distinguish benign from malignant pulmonary nodules. It is common to observe colonic uptake on whole-body FDG-PET images. Because patients with lung cancer also tend to be in the age group with the highest incidence of colon cancer, the authors tried to assess the efficacy of FDG-PET for detecting occult colon cancer in patients referred for the evaluation of lung nodules. Methods: The records of 500 consecutive patients referred for the evaluation of pulmonary nodules were reviewed retrospectively. Among the patients, 197 had no previous clinical or radiographic evidence of abnormalities in the gastrointestinal tract, and none had been found to have any cancer before undergoing an FDG-PET study. All colon lesions were verified either by histologic analysis or by clinical course. Results: Among the 197 patients analyzed, 59 had diffuse colonic uptake in various segments of the colon. Seventeen of the patients had focal colonic uptake, five of which were proved to be colon cancer. Conclusions: The routine use of FDG PET to characterize lung lesions significantly increases the probability of detecting unexpected extrathoracic disease. In these patients, the incidental finding of colon cancer had an important effect on their treatment and may prove to be very cost-effective.
引用
收藏
页码:628 / 632
页数:5
相关论文
共 20 条
[1]   Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings [J].
Abdel-Nabi, H ;
Doerr, RJ ;
Lamonica, DM ;
Cronin, VR ;
Galantowicz, P ;
Carbone, GM ;
Spaulding, MB .
RADIOLOGY, 1998, 206 (03) :755-760
[2]  
Bedigian MP, 1998, EUR J NUCL MED, V25, P659
[3]   PET and [F-18]-FDG in oncology: A clinical update [J].
Conti, PS ;
Lilien, DL ;
Hawley, K ;
Keppler, J ;
Grafton, ST ;
Bading, JR .
NUCLEAR MEDICINE AND BIOLOGY, 1996, 23 (06) :717-735
[4]   Thoracic FDG PET: State of the art [J].
Erasmus, JJ ;
McAdams, HP ;
Patz, EF ;
Goodman, PC ;
Coleman, RE .
RADIOGRAPHICS, 1998, 18 (01) :5-20
[5]   Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil [J].
Findlay, M ;
Young, H ;
Cunningham, D ;
Iveson, A ;
Cronin, B ;
Hickish, T ;
Pratt, B ;
Husband, J ;
Flower, M ;
Ott, R .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :700-708
[6]   Role of positron emission tomography scanning in evaluating gastrointestinal neoplasms [J].
Gupta, N ;
Bradfield, H .
SEMINARS IN NUCLEAR MEDICINE, 1996, 26 (01) :65-73
[7]  
Hannah A, 1996, J NUCL MED, V37, P1683
[8]   PET in oncology: Will it replace the other modalities? [J].
Hoh, CK ;
Schiepers, C ;
Seltzer, MA ;
Gambhir, SS ;
Silverman, DHS ;
Czernin, J ;
Maddahi, J ;
Phelps, ME .
SEMINARS IN NUCLEAR MEDICINE, 1997, 27 (02) :94-106
[9]   Whole-body FDG-PET imaging in the management of patients with cancer [J].
Hustinx, R ;
Bénard, F ;
Alavi, A .
SEMINARS IN NUCLEAR MEDICINE, 2002, 32 (01) :35-46
[10]  
Jacobson K, 1999, GASTROENTEROLOGY, V116, pA742